| Date | Title | Description |
| 01.03.2024 | Replicate Bioscience to Participate in Upcoming Investor and Scientific Conferences | SAN DIEGO, March 1, 2024 (PRNewswire) -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, will be participating in the follo... |
| 14.02.2024 | Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology | Replicate's srRNA vaccine elicited a protective immune response that met the WHO threshold for protection at unparalleled low doses
Threshold for protection achieved with just a single dose of vaccine
RBI-4000 well-tolerated at all doses te... |
| 29.01.2024 | Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies | ACDN-01 is the first RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease
Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first hal... |
| 29.01.2024 | Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies | ACDN-01 is the first RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease
Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half... |
| 25.01.2024 | First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers | Preliminary Phase 2 data in melanoma, renal cell carcinoma anticipated to be presented by mid-2024
LARKSPUR, Calif. (BUSINESS WIRE) -- Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the developmen... |
| 25.01.2024 | First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers | - |
| 05.01.2024 | Novel Compound Protects Against Infection by Virus that Causes COVID-19, Preliminary Studies Show | Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of COVID-19 in tests with hamsters |
| 05.01.2024 | Novel Compound Protects Against Infection by Virus that Causes COVID-19, Preliminary Studies Show | Stapled lipopeptides successfully deter infection by the SARS-CoV-2 virus and reduce the severity of COVID-19 in tests with hamsters
Clinical trial now under way of compound's effectiveness as a nasal spray in humans
Approach has the pote... |
| 18.12.2023 | Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors | Phase 2 study follows on positive Phase 1 data showing early anti-tumor activity in heavily pre-treated patients and well-tolerated safety profile |
| 18.12.2023 | Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors | Phase 2 study follows on positive Phase 1 data showing early anti-tumor activity in heavily pre-treated patients and well-tolerated safety profile
Phase 2 portion to assess AU-007 in combination with low-dose Proleukin®, with initial expan... |
| 14.12.2023 | Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models | Conducting entirely virtual screens of multi-billion molecule virtual libraries, Deep Apple can quickly identify hits that promote specific signaling in GPCRs and other target classes
San Francisco-based company created by ATP with academi... |
| 14.12.2023 | Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models | Conducting entirely virtual screens of multi-billion molecule virtual libraries, Deep Apple can quickly identify hits that promote specific signaling in GPCRs and other target classes |
| 07.12.2023 | Marengo Therapeutics and Kings College London Announce Publication in Science Advances Highlighting the Discovery of a New Approach to T Cell Activation | Antibodies to germline-encoded TCR β-chain alleles drive T cells to distinct memory-like effector states and reveal the potential to modulate the germline T cell repertoire. |
| 06.12.2023 | Marengo Therapeutics Announces Publication Describing STAR0602, a Novel, TCR-Targeting Cancer Immunotherapy, in Science Translational Medicine | Marengo's first pan-tumor Vβ T cell activator, STAR0602, expands Vβ6 T cells that drive potent, single agent anti-tumor activity via a distinct mechanism to anti-PD1 therapies |
| 13.11.2023 | Nereid Therapeutics Appoints Michael Kauffman as CEO | Seasoned industry executive with decades of success in drug discovery, development, regulatory approvals and commercialization will lead Nereid’s work to advance multiple programs towards the clinic |
| 13.11.2023 | Nereid Therapeutics Appoints Michael Kauffman as CEO | Seasoned industry executive with decades of success in drug discovery, development, regulatory approvals and commercialization will lead Nereid’s work to advance multiple programs towards the clinic
BOSTON, November 13, 2023 /PRNewswire/ -... |
| 08.11.2023 | Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO | Funds from ATP will support the progress of Ascidian’s lead program in ABCA4 retinopathies, including Stargardt disease, and advance key pipeline programs
in CNS and neuromuscular diseases |
| 08.11.2023 | Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO | Funds from ATP will support the progress of Ascidian’s lead program in ABCA4 retinopathies, including Stargardt disease, and advance key pipeline programs
in CNS and neuromuscular diseases
Ascidian anticipates filing an IND and initiating... |
| 06.11.2023 | Galvanize Therapeutics Announces Promising Data on the Aliya™ Pulsed Electric Field (PEF) System in Early-Stage Non-Small Cell Lung Cancer | SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies, unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SIT... |
| 06.11.2023 | Galvanize Therapeutics Announces Promising Data on the Aliya™ Pulsed Electric Field (PEF) System in Early-Stage Non-Small Cell Lung Cancer | SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies, unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SIT... |
| 03.11.2023 | New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting | Preliminary evidence of anti-tumor activity observed in heavily pre-treated patients, including those whose tumors progressed through checkpoint inhibitors
Further development of AU-007 to continue in combination with low-dose aldesleukin,... |
| 03.11.2023 | New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting | - |
| 14.10.2023 | New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeuti... | Interim data from an ongoing trial support overall mechanism of action of AU-007, a computationally designed human monoclonal antibody, in decreasing Tregs while increasing effector T cells and NK cells
Clinical efficacy and safety data fr... |
| 14.10.2023 | New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeuti... | - |
| 04.10.2023 | Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic... | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced the presentation of encouraging pha... |
| 04.10.2023 | Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutic... | - |
| 27.09.2023 | Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting | LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that new safety and efficacy data f... |
| 27.09.2023 | Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting | - |
| 20.09.2023 | Galvanize Therapeutics Begins U.S. Clinical Study Using Aliya™ Pulsed Electric Field (PEF) for Stage IV Non-Small Cell Lung Cancer or Metastasis to the Lung | First patient treated in the U.S. with Aliya PEF delivered via an endobronchial approach with robotic-assisted navigation |
| 20.09.2023 | Galvanize Therapeutics Begins U.S. Clinical Study Using Aliya™ Pulsed Electric Field (PEF) for Stage IV Non-Small Cell Lung Cancer or Metastasis to the Lung | First patient treated in the U.S. with Aliya PEF delivered via an endobronchial approach with robotic-assisted navigation
REDWOOD CITY, Calif. , Sept. 20, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc. today announced the treatment of t... |
| 12.09.2023 | Nine Square Therapeutics Awarded $4.5 Million Grant from The Michael J. Fox Foundation to Advance Development of Novel Parkin Activators | - |
| 12.09.2023 | Nine Square Therapeutics Awarded $4.5 Million Grant from The Michael J. Fox Foundation to Advance Development of Novel Parkin Activators | Nine Square is building a diversified portfolio of first-in-class drug candidates for genetically validated targets along the autophagy/lysosomal pathway
The company has identified compounds that promote Parkin activity to induce clearanc... |
| 12.09.2023 | Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine | SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA modalities and expand use of RNA treatments to... |
| 12.09.2023 | Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine | SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA modalities and expand use of RNA treatments to... |
| 05.09.2023 | BRIXADI® (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder | BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. |
| 05.09.2023 | BRIXADI® (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder | BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional.
PLYMOUTH MEETING, Pa., Sept. 5, 2023 /PRNewswire/ -- B... |
| 01.08.2023 | Aulos Bioscience Raises $20 Million in Series A Extension Financing From Apple Tree Partners | - |
| 01.08.2023 | Aulos Bioscience Raises $20 Million in Series A Extension Financing From Apple Tree Partners | Funds from ATP will continue to sustain the progress of Aulos’ novel IL-2 therapeutic AU-007 through a Phase 2 trial in solid tumor cancers
The additional funding is substantiated by interim data from Aulos’ ongoing Phase 1/2 trial release... |
| 11.07.2023 | Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner | Jacobson, an eminent research scientist working across disciplines including computational biophysics, physical chemistry, quantum mechanics, rational drug design, and protein structure prediction, has founded several successful companies i... |
| 11.07.2023 | Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner | Jacobson, an eminent research scientist working across disciplines including computational biophysics, physical chemistry, quantum mechanics, rational drug design, and protein structure prediction, has founded several successful companies i... |
| 10.07.2023 | Replicate Bioscience Appoints Rachael Lester as Chief Business Officer | Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team
SAN DIEGO, Calif., July 10, 2023 – Replicate Bioscience, a company pioneering novel... |
| 10.07.2023 | Replicate Bioscience Appoints Rachael Lester as Chief Business Officer | Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team |
| 27.06.2023 | Intergalactic Therapeutics Announces Positive Results for Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies in Non-Human Primates | Data from IG-002, Intergalactic's lead program, demonstrate persistent ABCA4 expression in non-human primate retinas over six months after a single administration
Findings build on 12-month durability data achieved in adult porcine retinas... |
| 27.06.2023 | Intergalactic Therapeutics Announces Positive Results for Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies in Non-Human Primates | Data from IG-002, Intergalactic's lead program, demonstrate persistent ABCA4 expression in non-human primate retinas over six months after a single administration |
| 19.06.2023 | Galvanize Therapeutics Completes Enrollment in Pivotal Trial of RheOx® System for Chronic Bronchitis | REDWOOD CITY, Calif., June 19, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field (PEF) therapies for COPD, soft tissue, and cardiac arrhythmias, has completed enrollment in the RheSolve pivotal ... |
| 19.06.2023 | Galvanize Therapeutics Completes Enrollment in Pivotal Trial of RheOx® System for Chronic Bronchitis | REDWOOD CITY, Calif., June 19, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field (PEF) therapies for COPD, soft tissue, and cardiac arrhythmias, has completed enrollment in the RheSolve pivotal ... |
| 12.06.2023 | Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG | Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billion
Chinook’s diversified p... |
| 12.06.2023 | Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG | Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billion |
| 05.06.2023 | Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease... | Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone
88% of patients treated with EFX combined with GLP-1 had normalized liver fat a... |
| 05.06.2023 | Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease... | Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone |
| 30.05.2023 | Galvanize Announces License Agreement and Partnership with Energenx Medical for its Technologies in China | License will maximize the availability of Pulsed Electric Field therapies for the population |
| 30.05.2023 | Galvanize Announces License Agreement and Partnership with Energenx Medical for its Technologies in China | License will maximize the availability of Pulsed Electric Field therapies for the population
Energenx has obtained Green Channel approval for RheOx, Galvanize's proprietary Pulsed Electric Field (PEF) system for the treatment of Chronic Br... |
| 25.05.2023 | Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells | New data in ASCO 2023 abstract show continued trend in decreasing Tregs and eosinophils, bolstering novel mechanism of action of AU-007, Aulos’ computationally designed antibody in the IL-2 class |
| 25.05.2023 | Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells | New data in ASCO 2023 abstract show continued trend in decreasing Tregs and eosinophils, bolstering novel mechanism of action of AU-007, Aulos’ computationally designed antibody in the IL-2 class
Initial anti-tumor activity has been observ... |
| 23.05.2023 | FDA News Release: FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder | Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, ... |
| 23.05.2023 | Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder | BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. |
| 23.05.2023 | Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder | BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses.
Patients currently on a transmucosal buprenorphine-containing product can be switched to an equivalent dose of BRIXADI Weekly or Monthly... |
| 23.05.2023 | FDA News Release: FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder | Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two formulations, ... |
| 16.05.2023 | Intergalactic Therapeutics to Host Virtual KOL Investor Event on May 23, 2023 | CAMBRIDGE, Mass., May 16, 2023 /PRNewswire/ -- Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today that it will host a virtual investor event with scientific experts in the ... |
| 16.05.2023 | Intergalactic Therapeutics to Host Virtual KOL Investor Event on May 23, 2023 | CAMBRIDGE, Mass., May 16, 2023 /PRNewswire/ -- Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today that it will host a virtual investor event with scientific experts in the ... |
| 11.05.2023 | Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting | Lead program, IG-002 targeting ABCA4 retinopathies demonstrated long-term, persistent protein expression over twelve months with a single administration |
| 11.05.2023 | Intergalactic Therapeutics to Present Preclinical Data Highlighting Potential of Its Non-Viral Gene Therapy Platform at the American Society of Gene and Cell Therapy 26th Annual Meeting | Lead program, IG-002 targeting ABCA4 retinopathies demonstrated long-term, persistent protein expression over twelve months with a single administration
Newly developed in vitro efficacy model highlights ability of non-viral gene therapy p... |
| 09.05.2023 | Ascidian Therapeutics to Present New Data From Its Lead Program Targeting ABCA4 Retinopathies at the ASGCT 2023 Annual Meeting | Latest six-month data from lead ABCA4 program demonstrate efficient and durable production of full-length ABCA4 protein generated via RNA exon editing in non-human primate retina
ABCA4 program advancing to IND filing, as Ascidian progresse... |
| 09.05.2023 | Ascidian Therapeutics to Present New Data From Its Lead Program Targeting ABCA4 Retinopathies at the ASGCT 2023 Annual Meeting | Latest six-month data from lead ABCA4 program demonstrate efficient and durable production of full-length ABCA4 protein generated via RNA exon editing in non-human primate retina |
| 01.05.2023 | With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets | Initial was created to take on undruggable disease-causing proteins by discriminately intercepting their translation in the exit tunnel of the ribosome |
| 01.05.2023 | With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets | Initial was created to take on undruggable disease-causing proteins by discriminately intercepting their translation in the exit tunnel of the ribosome
Initial’s platform brings together scientific breakthroughs from the labs of Jamie H.D.... |
| 20.04.2023 | Intergalactic Therapeutics to Present Updated Data From Its Non-Viral Gene Therapy Platform at the 2023 Retinal Cell and Gene Therapy Innovation Summit | Lead program, IG-002 targeting ABCA4 retinopathies, demonstrates durable 12-month expression of human ABCA4 protein using a single subretinal dose of DNA payload |
| 20.04.2023 | Intergalactic Therapeutics to Present Updated Data From Its Non-Viral Gene Therapy Platform at the 2023 Retinal Cell and Gene Therapy Innovation Summit | Lead program, IG-002 targeting ABCA4 retinopathies, demonstrates durable 12-month expression of human ABCA4 protein using a single subretinal dose of DNA payload
CAMBRIDGE, Mass., April 20, 2023 /PRNewswire/ -- Intergalactic Therapeutics, ... |
| 19.04.2023 | Replicate Bioscience Presents Preclinical srRNA Data at the American Association for Cancer Research Annual Meeting 2023 | Preclinical studies provide proof-of-concept for Replicate's novel srRNA platform and programs |
| 19.04.2023 | Replicate Bioscience Presents Preclinical srRNA Data at the American Association for Cancer Research Annual Meeting 2023 | Preclinical studies provide proof-of-concept for Replicate's novel srRNA platform and programs
RBI-1000, Replicate's precision immuno-oncology program in development as an off-the-shelf treatment, induced robust immunity to multiple acquir... |
| 18.04.2023 | Ascidian Therapeutics to Present Data From Its Lead Program Targeting ABCA4 Retinopathies at the Retinal Cell and Gene Therapy Innovation Summit and ARVO 2023 Annual Meeting | New six-month durability data from lead ABCA4 program demonstrate the most efficient and durable RNA exon editing ever reported in a large animal
Additional new data in human retinal explants is first-ever demonstration of RNA exon editing... |
| 18.04.2023 | Ascidian Therapeutics to Present Data From Its Lead Program Targeting ABCA4 Retinopathies at the Retinal Cell and Gene Therapy Innovation Summit and ARVO 2023 Annual Meeting | New six-month durability data from lead ABCA4 program demonstrate the most efficient and durable RNA exon editing ever reported in a large animal |
| 11.04.2023 | Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic | Leadership appointments come as Ascidian's lead program targeting ABCA4 retinopathies, including Stargardt disease, moves through IND-enabling studies |
| 11.04.2023 | Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic | Leadership appointments come as Ascidian's lead program targeting ABCA4 retinopathies, including Stargardt disease, moves through IND-enabling studies
BOSTON, April 11, 2023 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company fo... |
| 22.03.2023 | Marengo Therapeutics to Present a Late-Breaking Abstract at AACR Annual Meeting 2023 Highlighting Broad Application of its Novel TCR Vβ Targeting Platform | CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ repertoire to fight cancer and other diseases, today announced that the compa... |
| 22.03.2023 | Marengo Therapeutics to Present a Late-Breaking Abstract at AACR Annual Meeting 2023 Highlighting Broad Application of its Novel TCR Vβ Targeting Platform | CAMBRIDGE, Mass., March 22, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ repertoire to fight cancer and other diseases, today announced that the compa... |
| 20.03.2023 | Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer | BOSTON, March 20, 2023 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced today the appointment of Jay A. Barth, M.D., as Chief Medical Officer (CMO). With 25 years ... |
| 20.03.2023 | Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer | BOSTON, March 20, 2023 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced today the appointment of Jay A. Barth, M.D., as Chief Medical Officer (CMO). With 25 years ... |
| 15.03.2023 | Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies | Data for IG-002 show for the first time that a single subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable expression of human ABCA4 protein |
| 15.03.2023 | Intergalactic Therapeutics Announces Positive Preclinical Results of Its Non-Viral Gene Therapy Platform in ABCA4 Retinopathies | Data for IG-002 show for the first time that a single subretinal administration of a DNA payload encoding the human ABCA4 gene resulted in durable expression of human ABCA4 protein
Results support plan to advance lead program in ABCA4-rela... |
| 14.03.2023 | Replicate Bioscience Shares New Preclinical srRNA Data at American Association for Cancer Research Annual Meeting 2023 | Poster presentations provide data on Replicate's lead immuno-oncology candidate, RBI-1000, in targeting acquired resistance mutations and on another proof-of-concept study demonstrating the potential of Replicate's novel srRNA technology fo... |
| 14.03.2023 | Replicate Bioscience Shares New Preclinical srRNA Data at American Association for Cancer Research Annual Meeting 2023 | Poster presentations provide data on Replicate's lead immuno-oncology candidate, RBI-1000, in targeting acquired resistance mutations and on another proof-of-concept study demonstrating the potential of Replicate's novel srRNA technology fo... |
| 07.03.2023 | New Interventional Oncology Data Show Potential for Aliya™ Pulsed Electric Field (PEF) System in Treatment of Solid Tumors | Galvanize Therapeutics data presented at SIR 2023 include PEF safety and feasibility results in patients with non-small cell lung cancer, and pre-clinical results comparing PEF and radiofrequency ablation |
| 07.03.2023 | New Interventional Oncology Data Show Potential for Aliya™ Pulsed Electric Field (PEF) System in Treatment of Solid Tumors | Galvanize Therapeutics data presented at SIR 2023 include PEF safety and feasibility results in patients with non-small cell lung cancer, and pre-clinical results comparing PEF and radiofrequency ablation
PHOENIX, March 7, 2023 /PRNewswire... |
| 01.03.2023 | Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer | CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announ... |
| 01.03.2023 | Galvanize Therapeutics Announces First Human Use of QuickShot: A Novel Contact-Sensing, Large Area, Focal Pulsed Electric Field Mapping and Ablation Catheter | REDWOOD CITY, Calif., March 1, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc. today announced the first human investigational use of its large-area, focal, Pulsed Electric Field (PEF) ablation catheter called QuickShot™ in the QuickShot ... |
| 01.03.2023 | Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer | CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announ... |
| 01.03.2023 | Galvanize Therapeutics Announces First Human Use of QuickShot: A Novel Contact-Sensing, Large Area, Focal Pulsed Electric Field Mapping and Ablation Catheter | REDWOOD CITY, Calif., March 1, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc. today announced the first human investigational use of its large-area, focal, Pulsed Electric Field (PEF) ablation catheter called QuickShot™ in the QuickShot ... |
| 17.02.2023 | Gene editing: DNA versus RNA (Drug Discovery News) | Treating disease is often a matter of restoring the function of a specific protein, process, or pathway. But when a disease manifests in cellular chaos too widespread to correct or in drug targets that are lost altogether, researchers may r... |
| 17.02.2023 | Gene editing: DNA versus RNA (Drug Discovery News) | Researchers correcting the genetic causes of disease at the DNA or RNA level make their cases.
Treating disease is often a matter of restoring the function of a specific protein, process, or pathway. But when a disease manifests in cellula... |
| 01.02.2023 | First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors | - |
| 01.02.2023 | First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors | Dosing marks first time a computationally designed monoclonal antibody enters human trial in the U.S.
U.S. enrollment begins in North Carolina, with additional sites being planned nationwide
LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Biosci... |
| 27.01.2023 | Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | START-001 study leverages a biomarker-enriched tissue-agnostic approach to evaluate the activity of STAR0602 monotherapy in checkpoint inhibitor refractory advanced solid tumors
CAMBRIDGE, Mass., Jan. 27, 2023 /PRNewswire/ -- Marengo Thera... |
| 27.01.2023 | Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | START-001 study leverages a biomarker-enriched tissue-agnostic approach to evaluate the activity of STAR0602 monotherapy in checkpoint inhibitor refractory advanced solid tumors |
| 17.01.2023 | Why I invited investors into my lab: Adendra Therapeutics co-founder Caetano Reis e Sousa in conversation with The Francis Crick Institute | In December 2021, Apple Tree Partners (ATP), a leader in life sciences venture capital, announced the launch of Adendra Therapeutics Ltd, a spin-out of immunology research by Crick Principal Group Leader Caetano Reis e Sousa and his team. O... |
| 17.01.2023 | Why I invited investors into my lab: Adendra Therapeutics co-founder Caetano Reis e Sousa in conversation with The Francis Crick Institute | In December 2021, Apple Tree Partners (ATP), a leader in life sciences venture capital, announced the launch of Adendra Therapeutics Ltd, a spin-out of immunology research by Crick Principal Group Leader Caetano Reis e Sousa and his team. O... |
| 09.01.2023 | ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells | Aethon’s HapImmune™ platform, described in a recent publication in the journal Cancer Discovery, unites immunotherapy and targeted therapy
$30M in Series A funding, with $25M from Apple Tree Partners (ATP) and participation by NYU Langone ... |
| 09.01.2023 | ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells | |
| 06.01.2023 | Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer | BOSTON, Jan. 6, 2023 /PRNewswire/ -- Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today the appointment of Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer (CEO)... |
| 06.01.2023 | Intergalactic Therapeutics Appoints Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer | BOSTON, Jan. 6, 2023 /PRNewswire/ -- Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today the appointment of Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer (CEO)... |
